Follow
Krishnaprasad Baby
Krishnaprasad Baby
Research Scholar, Manipal College of Pharmaceutical Sciences
Verified email at learner.manipal.edu
Title
Cited by
Cited by
Year
Targeting SARS-CoV-2 main protease: a computational drug repurposing study
K Baby, S Maity, CH Mehta, A Suresh, UY Nayak, Y Nayak
Archives of medical research 52 (1), 38-47, 2021
582021
Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19
K Baby, S Maity, CH Mehta, A Suresh, UY Nayak, Y Nayak
F1000Research 9, 2020
542020
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
K Baby, S Maity, CH Mehta, A Suresh, UY Nayak, Y Nayak
European Journal of Pharmacology 896, 173922, 2021
422021
Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19, F1000Research, 2020, 9, 1166
K Baby, S Maity, CH Mehta, A Suresh, UY Nayak, Y Nayak
This article is licensed under a Creative Commons Attribution-NonCommercial 3, 0
7
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis
NN Dsouza, V Alampady, K Baby, S Maity, BH Byregowda, Y Nayak
Inflammopharmacology 31 (3), 1167-1182, 2023
62023
In silico drug repurposing of penicillins to target main protease mpro of SARS-CoV-2
B Krishnaprasad, S Maity, C Mehta, A Suresh, UY Nayak, Y Nayak
Pharmaceutical Sciences 26 (Covid-19), S52-S62, 2020
62020
Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer
K Baby, S Maity, CH Mehta, UY Nayak, GG Shenoy, KSR Pai, ...
Scientific Reports 13 (1), 7947, 2023
42023
Network pharmacology and in silico approaches to uncover multitargeted mechanism of action of Zingiber zerumbet rhizomes for the treatment of idiopathic pulmonary fibrosis
BH Byregowda, K Baby, S Maity, UY Nayak, G S, SM Fayaz, Y Nayak
F1000Research 13, 216, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–8